- Details
- Alexander Wyatt from the University of British Columbia joins Ashish Kamat in a discussion on the genomic correlates of Bacillus Calmette-Guerin (BCG) responsive and relapsed non-muscle invasive bladder cancer. Dr. Wyatt shares recent study findings exploring links between common genomic driver alternations and BCG unresponsiveness and also data looking at genomic variables in the context of initi...
|
- Details
- In this conversation with Ashish Kamat, MD, Arjun Balar, MD, MBBS, discusses testing the concept of effectively treating bladder cancer without needing chemotherapy in the non-muscle-invasive disease space, specifically patients with high-risk carcinoma in situ, with or without papillary tumors that had become unresponsive to Bacillus Calmette-Guerin (BCG) based on the current Federal Drug Adminis...
|
- Details
- Anne Schuckman, MD, MBBS, presents a summary of her plenary session presentation from the AUA 2020 live virtual conference on benefits of Blue Light Cystoscopy (BLC ® ) with Cysview ® , in a conversation with Ashish Kamat, MD. Dr. Schuckman details how Cysview can be used to visualize bladder tumors and highlights benefits arising from this technique including an increased ability to resect the tu...
|
- Details
- Stephen Williams discusses the macro and microeconomics of using blue light cystoscopy with CYSVIEW ® in nonmuscle invasive bladder cancer compared to white light cystoscopy alone. Dr. Williams notes that cancer care is expected to increase from $158 to $174 billion dollars between 2010 and 2020 due to increasing cancer incidence, improved survival outcomes, and an expanding healthcare market. Cos...
|
- Details
- Ashish Kamat welcomes leading bladder cancer experts Paolo Gontero and Bernard Bochner to engage in a debate considering a hypothetical patient with nonmuscle invasive high-grade T1 disease. Dr. Bochner starts by addressing different treatment options for patients presenting with T1 disease while acknowledging that T1 disease is a spectrum and can be variably invasive. He discusses BCG as a treatm...
|
- Details
- Alicia Morgans and Sam Chang discuss the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines. Dr. Chang, a member of the bladder cancer guidelines committee, notes that while the guidelines are in the process of being updated since these were last updated in 2017, they serve as an algorithm for all clinicians on how to evaluate patients and risk stratification....
|
- Details
- Trinity Bivalacqua joins Ashish Kamat to discuss the role of blue light cystoscopy in bladder cancer treatment, specifically regarding non-muscle invasive disease. Dr. Bivalacqua emphasizes how risk stratification allows for personalization of care and highlights a case study of a patient with high-risk non-muscle invasive bladder cancer. Dr. Bivalacqua also explains how blue light cystoscopy can...
|
- Details
- Michael O'Donnell shares his insight into managing the current BCG shortage crisis, highlighting ways to make the most out of the current supply and explains a few alternative intravesical agents that could be used in place of BCG for treating patients with bladder cancer. Dr. O'Donnell explains how risk can be assessed while prioritizing high-risk patients and shares advice as to how treatment pl...
|
- Details
- Joshua Meeks joins Alicia Morgans to review his approach to cystoscopy using blue light and Cysview®, and how to best choose patients that will maximally benefit from that kind of technology. Dr. Meeks and Dr. Morgans also review the new approval of pembrolizumab in the BCG unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor...
|
- Details
- Joshua Meeks joins Alicia Morgans to discuss the current BCG shortage and its implications for treatment options in the bladder cancer community. Dr. Meeks highlights clinical data on the matter presented by other clinicians at the conference, as well as his own personal expertise on how he manages the patient selection and the risk stratification process for BCG resources in his own clinic. Biogr...
|
